Table 1.
Characteristics of living donor kidney transplant recipients, by desensitization intensity (%)
| Characteristics | CLDKT | ILDKT a | P value | ||
|---|---|---|---|---|---|
| None (n = 260) | Low (n = 47) | Moderate (n = 74) | High (n = 94) | ||
| Recipient | |||||
| Type of ILDKT | <.001 | ||||
| ABOi | 10.6 | 12.1 | 20.2 | ||
| HLAi | 89.4 | 75.7 | 56.4 | ||
| ABOi & HLAi | 0.0 | 12.2 | 23.4 | ||
| Age (years), mean (SD) | 48.0 (15.3) | 49.8 (14.4) | 46.7 (15.8) | 45.5 (14.1) | .4 |
| Female sex | 41.9 | 46.8 | 50.0 | 57.4 | .07 |
| Race/ethnicity | 1.0 | ||||
| White | 70.4 | 76.6 | 73.0 | 70.2 | |
| Black | 22.7 | 17.0 | 20.2 | 21.3 | |
| Other | 6.9 | 6.4 | 6.8 | 8.5 | |
| BMI (kg/m2), mean (SD) | 27.2 (6.2) | 27.1 (5.3) | 26.9 (5.4) | 26.9 (6.4) | 1.0 |
| Cause of ESRD | .3 | ||||
| Glomerular diseases | 21.9 | 23.4 | 29.7 | 23.4 | |
| FSGS | 10.8 | 6.4 | 12.2 | 14.9 | |
| Diabetes | 12.3 | 8.5 | 8.1 | 12.8 | |
| Hypertension | 24.6 | 25.5 | 17.6 | 21.3 | |
| Polycystic kidney disease | 13.5 | 6.4 | 5.4 | 8.5 | |
| Other | 16.9 | 29.8 | 27.0 | 19.1 | |
| Years on dialysis, median (IQR) | 0.4 (0.0, 1.6) | 1.1 (0.0, 3.7) | 2.3 (0.2, 4.4) | 2.6 (1.0, 5.0) | <.001 |
| Number of previous transplants | <.001 | ||||
| 0 | 91.1 | 48.9 | 47.3 | 54.2 | |
| 1 | 7.7 | 40.4 | 39.2 | 33.0 | |
| ≥2 | 1.2 | 10.7 | 13.5 | 12.8 | |
| cPRA (%) | <.001 | ||||
| 0 | 90.3 | 40.4 | 41.9 | 29.8 | |
| 1‐20 | 3.1 | 4.3 | 2.7 | 5.3 | |
| 21‐79 | 5.8 | 25.5 | 23.0 | 19.2 | |
| ≥80 | 0.8 | 29.8 | 32.4 | 45.7 | |
| CMV | .2 | ||||
| D+/R‐ | 14.6 | 14.9 | 13.5 | 10.6 | |
| D+/R+ | 29.2 | 38.3 | 40.5 | 43.6 | |
| Other | 56.2 | 46.8 | 46.0 | 45.8 | |
| Donor | |||||
| Age, mean (SD) | 44.0 (12.6) | 43.9 (14.0) | 44.7 (11.2) | 44.9 (13.1) | .9 |
| Race/ethnicity | .2 | ||||
| White | 76.5 | 78.7 | 68.9 | 66.0 | |
| Black | 16.2 | 17.0 | 16.2 | 23.4 | |
| Other | 7.3 | 4.3 | 14.9 | 10.6 | |
| Related donor | 47.3 | 36.2 | 29.7 | 25.5 | .001 |
| Immunosuppression | |||||
| Desensitization regimen | |||||
| Rituximab | — | 44.7 | 58.1 | 84.0 | <.001 |
| Eculizumab | — | 10.6 | 6.8 | 21.3 | .02 |
| Bortezomib | — | 0.0 | 0.0 | 4.3 | .2 |
| C1 esterase inhibitor | — | 0.0 | 0.0 | 9.6 | .002 |
| Splenectomy | .002 | ||||
| Yes | — | 0.0 | 0.0 | 10.6 | |
| Previous history | — | 0.0 | 1.4 | 2.1 | |
| High‐dose IVIg | — | 0.0 | 0.0 | 1.1 | 1.0 |
| Number of desensitization agents received | <.001 | ||||
| 0 | — | 44.7 | 39.2 | 10.7 | |
| 1 | — | 55.3 | 55.4 | 58.5 | |
| 2 | — | 0.0 | 5.4 | 20.2 | |
| 3 | — | 0.0 | 0.0 | 8.5 | |
| 4 | — | 0.0 | 0.0 | 2.1 | |
| Induction immunosuppression | <.001 | ||||
| No induction | 3.5 | 0.0 | 0.0 | 0.0 | |
| Thymoglobulin only | 91.9 | 87.2 | 86.5 | 81.9 | |
| Basiliximab only | 4.6 | 12.8 | 10.8 | 8.5 | |
| Both | 0.0 | 0.0 | 2.7 | 9.6 | |
Abbreviations: BMI, body mass index; CLDKT, compatible living donor kidney transplantation; cPRA, calculated panel reactive antibody; CMV; cytomegalovirus; D, donor; ESRD, end‐stage renal disease; FSGS; focal segmental glomerulosclerosis; IQR, interquartile range; ILDKT, incompatible living donor kidney transplantation; LDKT living donor kidney transplantation; R, recipient; SD, standard deviation.
a
Low (0‐4 plasmaphereses), moderate (5‐9 plasmaphereses), and high (≥10 plasmaphereses).